Realizing the vision of a new class of medicines based on modulating the electrical signalling patterns of the peripheral nervous system needs a firm research foundation. Here, an interdisciplinary community puts forward a research roadmap for the next 5 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Famm, K. et al. A jump start for electroceuticals. Nature 496, 159–161 (2013).
Gassler, J. P. & Bisognano, J. D. Baroreflex activation therapy in hypertension. J. Hum. Hypertens. http://dx.doi.org/10.1038/jhh.2013.139 (2014).
Strollo, P. J. Jr et al. Upper-airway stimulation for obstructive sleep apnea. N. Engl. J. Med. 370, 139–149 (2014).
Alivisatos, A. P. et al. Nanotools for neuroscience and brain activity mapping. ACS Nano. 7, 1850–1866 (2013).
Marblestone, A. H. et al. Physical principles for scalable neural recording. Front. Comput. Neurosci. 7, 137 (2013).
Acknowledgements
The views and opinions contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the US National Institutes of Health. Douglas Weber, Ph.D., is a Program Manager at the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). DARPA has approved this article for public release, and distribution is unlimited. The views, opinions, and/or findings contained in this article/presentation are those of the author(s)/presenter(s) and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the US Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.B. and K.F. are presently employees of GlaxoSmithKline, as indicated in the affiliations.
V.G. is a co-founder of Circuit Therapeutics and holds related intellectual property and stock (less than 5%). At the time of writing, V.G. receives no research funding, royalties, or consultant fees from any for-profit organization.
P.A. is sponsored by Charles Stark Draper Laboratory.
W.M.G. receives funding through GlaxoSmithKline's Bioelectronics R&D programme and research support from Medtronic, Stryker and Ethicon. He holds equity positions in NDI Medical, SPR Therapeutics and Deep Brain Innovations, and is a paid consultant for Autonomic Technologies, Circuit Therapeutics, NeuroAccess Technologies, NeuroTronik, NDI Medical, SetPoint Medical and St. Jude Medical.
V.P. is a paid Consultant to GlaxoSmithKline, Bioelectronics R&D and receives funding through GlaxoSmithKline's Bioelectronics R&D programme.
B.M. is a paid consultant to GlaxoSmithKline.
P.P. receives funding through GlaxoSmithKline's Bioelectronics R&D programme and is a co-founder of Enterowave, Enterx, gIQ. He has several patents in the field of electrical stimulation in various stages of being licensed to different companies.
Supplementary information
Supplementary information S1 (box)
Bioelectronic medicines: the detailed research roadmap (PDF 305 kb)
Related links
Related links
FURTHER INFORMATION
Bioelectronics R&D — Million Dollar Innovation Challenge (GlaxoSmithKline)
Rights and permissions
About this article
Cite this article
Birmingham, K., Gradinaru, V., Anikeeva, P. et al. Bioelectronic medicines: a research roadmap. Nat Rev Drug Discov 13, 399–400 (2014). https://doi.org/10.1038/nrd4351
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4351
